News

Just a summary of all the news articles that we could source from different places. A good way to make an investment decision is also to look at how actively the company is engaging with news sources to keep them in the news. In this day and age its critical to have a media presence.

Please consider a small donation if you think this website provides you with relevant information  

   
Date Title Source
2024-03-11 4:7:40 am Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN) GlobeNewsWire
2024-02-26 1:30:0 pm Travere Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
2024-02-23 4:5:0 am Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy GlobeNewswire
2024-02-22 11:0:0 pm CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy CNW Group
2024-02-15 1:1:0 pm Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results GlobeNewswire
2024-02-08 1:30:0 pm Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results GlobeNewswire
2024-02-01 1:30:0 pm Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference GlobeNewswire
2024-01-25 1:5:0 pm Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations GlobeNewswire
2024-01-08 4:0:0 am Travere Therapeutics Provides Corporate Update and 2024 Outlook GlobeNewswire
   

Please consider a small donation if you think this website provides you with relevant information